Eric S Hall1, Barbara T Isemann2, Scott L Wexelblatt3, Jareen Meinzen-Derr4, Jason R Wiles5, Sharon Harvey2, Henry T Akinbi3. 1. Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. Electronic address: eric.hall@cchmc.org. 2. University of Cincinnati Medical Center, Cincinnati, OH. 3. Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Cincinnati College of Medicine, Cincinnati, OH. 4. Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 5. Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Abstract
OBJECTIVES: To compare the duration of opioid treatment and length of stay among infants treated for neonatal abstinence syndrome (NAS) by using a pilot buprenorphine vs conventional methadone treatment protocol. STUDY DESIGN: This retrospective cohort analysis evaluated infants who received pharmacotherapy for NAS at 6 hospitals in Southwest Ohio from January 2012 through August 2014. A single neonatology provider group used a standardized methadone protocol across all 6 hospitals. However, at one of the sites, infants were managed with a buprenorphine protocol unless they had experienced chronic in utero exposure to methadone. Linear mixed models were used to calculate adjusted mean duration of opioid treatment and length of inpatient hospitalization with 95% CIs in infants treated with oral methadone compared with sublingual buprenorphine. The use of adjunct therapy was examined as a secondary outcome. RESULTS: A total of 201 infants with NAS were treated with either buprenorphine (n = 38) or methadone (n = 163) after intrauterine exposure to short-acting opioids or buprenorphine. Buprenorphine therapy was associated with a shorter course of opioid treatment of 9.4 (CI 7.1-11.7) vs 14.0 (12.6-15.4) days (P < .001) and decreased hospital stay of 16.3 (13.7-18.9) vs 20.7 (19.1-22.2) days (P < .001) compared with methadone therapy. No difference was detected in the use of adjunct therapy (23.7% vs 25.8%, P = .79) between treatment groups. CONCLUSION: The choice of pharmacotherapeutic agent is an important determinant of hospital outcomes in infants with NAS. Sublingual buprenorphine may be superior to methadone for management of NAS in infants with select intrauterine opioid exposures.
OBJECTIVES: To compare the duration of opioid treatment and length of stay among infants treated for neonatal abstinence syndrome (NAS) by using a pilot buprenorphine vs conventional methadone treatment protocol. STUDY DESIGN: This retrospective cohort analysis evaluated infants who received pharmacotherapy for NAS at 6 hospitals in Southwest Ohio from January 2012 through August 2014. A single neonatology provider group used a standardized methadone protocol across all 6 hospitals. However, at one of the sites, infants were managed with a buprenorphine protocol unless they had experienced chronic in utero exposure to methadone. Linear mixed models were used to calculate adjusted mean duration of opioid treatment and length of inpatient hospitalization with 95% CIs in infants treated with oral methadone compared with sublingual buprenorphine. The use of adjunct therapy was examined as a secondary outcome. RESULTS: A total of 201 infants with NAS were treated with either buprenorphine (n = 38) or methadone (n = 163) after intrauterine exposure to short-acting opioids or buprenorphine. Buprenorphine therapy was associated with a shorter course of opioid treatment of 9.4 (CI 7.1-11.7) vs 14.0 (12.6-15.4) days (P < .001) and decreased hospital stay of 16.3 (13.7-18.9) vs 20.7 (19.1-22.2) days (P < .001) compared with methadone therapy. No difference was detected in the use of adjunct therapy (23.7% vs 25.8%, P = .79) between treatment groups. CONCLUSION: The choice of pharmacotherapeutic agent is an important determinant of hospital outcomes in infants with NAS. Sublingual buprenorphine may be superior to methadone for management of NAS in infants with select intrauterine opioid exposures.
Authors: Jason N Moore; Marc R Gastonguay; Chee M Ng; Susan C Adeniyi-Jones; David E Moody; Wenfang B Fang; Michelle E Ehrlich; Walter K Kraft Journal: Clin Pharmacol Ther Date: 2018-04-28 Impact factor: 6.875
Authors: Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori Journal: Drug Saf Date: 2016-10 Impact factor: 5.606
Authors: Neera K Goyal; Jessica F Rohde; Vanessa Short; Stephen W Patrick; Diane Abatemarco; Esther K Chung Journal: Pediatrics Date: 2020-01-02 Impact factor: 7.124
Authors: Rosalyn Singleton; Amanda Slaunwhite; Mary Herrick; Matthew Hirschfeld; Laura Brunner; Christine Hallas; Sarah Truit; Sally Hanson; Margaret Young; Evelyn Rider Journal: Int J Circumpolar Health Date: 2019-12 Impact factor: 1.228
Authors: Andrew E Weller; Richard C Crist; Benjamin C Reiner; Glenn A Doyle; Wade H Berrettini Journal: Cold Spring Harb Perspect Med Date: 2021-03-01 Impact factor: 6.915